Hexarelin vs ipamorelin: how these two GH secretagogues differ

Last updated 2026-07-24

what are hexarelin and ipamorelin, exactly

Both are synthetic growth hormone secretagogues (GHS), small peptides built to mimic ghrelin and activate the growth hormone secretagogue receptor, GHS-R1a, in the pituitary and hypothalamus. That's the whole family resemblance. Hexarelin is a hexapeptide developed in the 1990s as one of the earlier, more potent GHRPs (growth hormone releasing peptides). Ipamorelin came slightly later, explicitly designed to be more selective. The 1998 paper that introduced ipamorelin to the literature calls it "the first selective growth hormone secretagogue," reporting that it releases GH from the pituitary without meaningfully stimulating ACTH, cortisol, or prolactin release the way earlier peptides in its class did ^[1]. That selectivity claim is the entire reason ipamorelin displaced hexarelin and GHRP-6 in a lot of later research and compounding formulations. Structurally, both came out of a broader medicinal chemistry effort to find orally active and injectable GH secretagogues. A 1998 Journal of Medicinal Chemistry paper on novel orally active GH secretagogues, and a companion paper describing a new series of potent GHRPs derived from ipamorelin, document how researchers iterated on the pentapeptide GHRP-6 scaffold to reduce off-target activity while keeping GH-releasing potency ^[2][3]. Ipamorelin itself is a pentapeptide; hexarelin is a hexapeptide with a different side chain chemistry that gives it stronger receptor binding but less pathway specificity.

how do their mechanisms of action actually differ

Both peptides are GHS-R1a agonists, meaning they bind the same receptor ghrelin binds and trigger the same downstream signal: a pulse of growth hormone from the anterior pituitary. Where they diverge is in what else they touch on the way there. Hexarelin has a broader pharmacological footprint. Beyond GH release, it has been studied for cardiovascular effects, appetite stimulation, and it interacts with pathways tied to cortisol and prolactin secretion more than ipamorelin does. Ipamorelin's original characterization paper specifically contrasts it with GHRP-6 and other early secretagogues on this point, noting minimal ACTH/cortisol and prolactin co-release ^[1]. A 2004 paper on ipamorelin's effect on pancreatic insulin release describes a distinct, GH-independent action on islet cells in rat models, which is a mechanism worth knowing about separately from the pituitary story ^[4]. There's also a documented GH-independent adiposity signal. A 2001 Biochemical and Biophysical Research Communications paper found that GH secretagogues as a class can stimulate adiposity through pathways that don't require GH itself, which complicates the simple "more GH equals more fat loss" narrative for the whole peptide family, hexarelin and ipamorelin included ^[5].

which one is more selective, and does selectivity matter

Ipamorelin is the more selective compound, full stop. That selectivity is the reason it exists as a distinct molecule rather than a hexarelin variant. The 1998 European Journal of Endocrinology paper that coined the "selective growth hormone secretagogue" description for ipamorelin found it stimulated GH release comparably to other secretagogues of its era while sparing the cortisol and prolactin response ^[1]. Hexarelin, by contrast, is older chemistry with a wider net. It's more potent milligram for milligram at hitting the GHS-R1a receptor, but that potency comes with more spillover into ACTH-cortisol signaling and prolactin. Whether that matters depends on what you're optimizing for. If the appeal of GH secretagogues is a gentler, more physiologic pulse of GH without stacking on extra cortisol (which itself works against some of the body composition goals people are chasing), ipamorelin's selectivity is the whole point. If raw potency at the receptor is what matters for a specific research application, hexarelin's stronger binding is the tradeoff people cite. Neither framing is backed by head-to-head human trials comparing the two directly; most of what we know comes from separate lines of animal and early pharmacology work, not a controlled comparison study.

what does the evidence actually show for ipamorelin

Ipamorelin has more published pharmacology than hexarelin, largely because it became the preferred selective secretagogue for further study. Here's what's actually been shown, and where. In rats, ipamorelin induced longitudinal bone growth in a 1999 Growth Hormone & IGF Research study ^[6], and a related 2000 Journal of Endocrinology paper found ipamorelin and GHRP-6 both increased bone mineral content in adult female rats ^[7]. A 2001 paper in the same journal found ipamorelin counteracted glucocorticoid-induced decreases in bone formation in adult rats, suggesting a protective role against steroid-induced bone loss in that model ^[8]. A 2002 histopathology paper looked at chronic ipamorelin treatment in young female rats and characterized the somatotroph (GH-producing cell) response in vitro ^[9]. Human pharmacokinetic data exists too. A 1999 Pharmaceutical Research paper modeled the pharmacokinetics and pharmacodynamics of ipamorelin in human volunteers ^[10], and a 1998 Xenobiotica paper evaluated its pharmacokinetics including nasal absorption routes ^[11]. A 2012 Analytical Chemistry paper mapped the metabolism of growth hormone releasing peptides generally, including ipamorelin ^[12], and a 2015 Drug Testing and Analysis paper identified ipamorelin metabolites in human urine after nasal administration, which matters for anti-doping detection work ^[13]. Outside bone and pituitary biology, ipamorelin has a completely separate research thread in GI motility. A 2009 Journal of Pharmacology and Experimental Therapeutics paper and later 2012 Journal of Experimental Pharmacology paper both found ipamorelin improved gastric dysmotility in rodent models of postoperative ileus ^[14][15]. That built up to a 2014 prospective, randomized, controlled proof-of-concept study in actual bowel resection patients, testing ipamorelin against postoperative ileus ^[16]. That's one of the only controlled human trials in this entire peptide family, and it's worth knowing it exists. A 2020 Journal of Experimental Pharmacology paper also found ghrelin mimetics, ipamorelin included, attenuated visceral and somatic nociception (pain signaling) in animal models ^[17].

what does the evidence actually show for hexarelin

Hexarelin has a longer history but a thinner recent research trail compared to ipamorelin, at least in the sources compiled here. Most of what's documented about it comes through comparison studies where it's used as a reference compound for other secretagogues rather than as the primary subject. The 1998 papers on novel orally active GH secretagogues and on new GHRP-6-derived peptides both use hexarelin-class chemistry as part of the structure-activity comparison that led to ipamorelin ^[2][3]. A 2001 Bioorganic & Medicinal Chemistry Letters paper on hybrid secretagogues combining NN703 and ipamorelin chemistry references this same lineage ^[18]. A 2017 Drug Testing and Analysis paper on structure-activity relationships for peptidic GH secretagogues covers the class broadly, including how side-chain differences between compounds like hexarelin and ipamorelin change receptor binding and off-target activity ^[19]. The honest summary: hexarelin's core GH-releasing action at GHS-R1a is well established from decades-old pharmacology, but it has not accumulated the newer specific human trial data that ipamorelin picked up through the ileus research line. If you're looking for a hexarelin equivalent to the 2014 ipamorelin bowel resection trial ^[16], it doesn't appear in the current literature compiled here.

hexarelin vs ipamorelin: side by side

is either one FDA-approved, and how are they legally obtained

Neither hexarelin nor ipamorelin is an FDA-approved drug for any human indication. You won't find either in the Drugs@FDA database of approved products ^[20]. Both exist in the research and compounding space, not as approved therapeutics. Compounding pharmacies can legally prepare certain substances under section 503A of the Food, Drug, and Cosmetic Act (21 U.S.C. 353a), which allows compounding from bulk drug substances that meet specific criteria, generally tied to either being a component of an FDA-approved drug or appearing on FDA's 503A bulks list under 21 CFR 216.23 ^[21][22]. There's a separate, more restrictive bulks list for 503B outsourcing facilities under 21 CFR 216.24 ^[23]. FDA maintains its own guidance page on bulk drug substances used in compounding under 503A ^[24], plus a running list of substances nominated for that use ^[25]. This regulatory detail matters because it's the difference between a legitimate compounding pathway and a gray-market vial from an unregulated seller. A 2018 Growth Hormone & IGF Research paper analyzed black market growth-promoting products and found meaningful discrepancies between labeled and actual content, a real quality control problem for anyone sourcing peptides outside a regulated pharmacy chain ^[26]. If you're researching where these compounds legitimately come from, read buy ipamorelin for the sourcing side of this question.

what's the actual product on the market: is there a standalone ipamorelin option

No. There is no standalone ipamorelin product on the market through legitimate compounding channels. Where ipamorelin is available, it's dispensed as part of a tesamorelin/ipamorelin blend, combining ipamorelin's GHS-R1a action with tesamorelin, a GHRH analog that works through a separate receptor pathway. This is a meaningful distinction from hexarelin, which when available tends to be sold as a single-compound product rather than paired with a GHRH analog. The tesamorelin/ipamorelin pairing reflects a common pharmacology rationale: GHRH analogs and ghrelin-mimetic secretagogues act through different receptors and different points in the GH-release cascade, so combining them is a mechanistically distinct approach from either single compound alone, more than a marketing bundle. If you're mapping out how a combination product's dosing works in practice, the cjc-1295 ipamorelin dosage calculator and reconstitute cjc ipamorelin guides cover the practical mechanics, and ipamorelin dosage covers dosing considerations specific to ipamorelin itself.

what do we know about side effects and safety for each

Neither compound has the kind of large, controlled human safety database that an FDA-approved drug carries, so "safety profile" here means what's been observed in the available animal work, small human pharmacology studies, and adjacent peptide research, not a settled clinical answer. For ipamorelin, the consistent theme across its literature is a comparatively narrow side-effect footprint relative to older secretagogues, largely because of its selectivity for GH release over cortisol and prolactin pathways ^[1]. A 2009 Growth Hormone & IGF Research paper looked at GH and GH secretagogue effects on nitrogen balance and urea synthesis in steroid-treated rats, relevant to muscle-wasting contexts ^[27]. Separately, a 2024 Physiology & Behavior paper found that ipamorelin and the related compound anamorelin both inhibited cisplatin-induced weight loss in ferrets, with anamorelin additionally showing anti-emetic effects through a central mechanism, a finding specific to that chemotherapy-induced wasting model and not a general weight-management claim ^[28]. For hexarelin, the compiled sources here don't include a dedicated modern safety study; its side-effect profile is inferred mostly from its broader receptor activity and older comparative pharmacology, which flagged more cortisol and prolactin involvement than ipamorelin ^[1][19]. Neither peptide's animal safety data should be read as a guarantee of human safety at any particular dose; that's a gap, not a reassurance. For a fuller rundown of documented and theoretical ipamorelin side effects, see ipamorelin side effects.

do either of these have real clinical or medical research applications beyond bodybuilding

Yes, and this is where the actual peer-reviewed interest in these peptides lives, separate from the bodybuilding-forum framing both compounds picked up online. Orthopaedic and sports medicine journals have taken a fresh look at peptide therapies generally. A 2026 Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews paper covers therapeutic peptides in orthopaedics broadly, including applications and open challenges ^[29]. A 2026 American Journal of Sports Medicine paper frames injectable peptide therapy as an emerging area physicians in sports medicine need a primer on ^[30], and a 2026 Sports Medicine paper specifically reviews safety and efficacy data for approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[31]. A 2026 JBJS Reviews paper does a structured narrative review of injectable peptides in sports medicine, covering evidence, safety, and anti-doping implications ^[32], which matters given that ipamorelin metabolites have specifically been characterized in urine drug testing research ^[13]. On the metabolic and endocrine side, a 2026 International Journal of Molecular Sciences paper reviews therapeutic peptides across aesthetic, metabolic, and endocrine conditions ^[33], and a 2026 Frontiers in Aging paper looks at therapeutic peptides in gerontology, mechanisms relevant to healthy aging research ^[34]. And specific to hypogonadal men, a 2020 Translational Andrology and Urology paper examines GH secretagogues' role in managing body composition in hypogonadal males, beyond androgen receptor-targeted therapy ^[35]. None of this amounts to an approved indication for either hexarelin or ipamorelin. It does show these compounds are an active area of legitimate academic interest well past the supplement-forum discussion that made them popular in the first place. For the broader mechanism picture on ipamorelin specifically, see the ipamorelin overview.

what about hexarelin and desensitization, and does ipamorelin have the same problem

One recurring concern with hexarelin in older literature is receptor desensitization: repeated dosing of potent secretagogues can blunt the GH pulse over time as the pituitary's response diminishes. This is a documented concern in GH secretagogue pharmacology broadly, tied to how strongly and how often a compound drives GHS-R1a. Ipamorelin's selectivity and comparatively gentler action at the receptor is often cited as a reason it may be less prone to this than more potent, less selective secretagogues like hexarelin, but the compiled sources here don't include a dedicated head-to-head desensitization trial comparing the two directly. That's a real gap. Anyone telling you with certainty that ipamorelin "never" causes desensitization while hexarelin "always" does is overstating what the controlled data actually shows. What's fair to say: the mechanism for concern (repeated strong receptor agonism blunting pituitary responsiveness) is real pharmacology, and ipamorelin's lower potency and selectivity make it a plausible candidate for less of this effect, without that being formally proven in a comparison study.

which should a researcher actually choose

If the goal is the gentlest, most selective GH pulse with the least cortisol and prolactin spillover, ipamorelin is the better-documented, more selective choice, and it's the one with an actual controlled human trial behind it (the 2014 postoperative ileus study) ^[16], plus a deeper bench of rodent bone and GI motility data ^{[6][7][8][14][15]}. If raw receptor potency is the priority and some cortisol/prolactin co-release is an acceptable tradeoff, hexarelin's older, stronger chemistry is the one people reach for, though the modern peer-reviewed literature specific to hexarelin is thinner than what's accumulated for ipamorelin in the last decade. Neither is FDA-approved, and neither should be sourced from an unregulated seller. A 2018 analysis of black market growth-promoting products found real content and purity problems in that space ^[26], which is exactly the risk a legitimate compounding pathway under 503A is meant to avoid ^[21][22]. Where ipamorelin is dispensed through Ipamorelin Co, it's provided as part of a tesamorelin/ipamorelin blend through a provider-reviewed process and a named compounding pharmacy partner, not sold as a standalone vial. That's a meaningfully different sourcing model than a peptide bought off an unregulated site.

Frequently asked questions

is hexarelin stronger than ipamorelin?

Hexarelin binds the GHS-R1a receptor more potently per dose than ipamorelin, based on the structure-activity comparisons from the medicinal chemistry papers that led to ipamorelin's development ^[2][3][19]. But that added potency comes with more cortisol and prolactin co-release, which ipamorelin was specifically engineered to minimize ^[1]. "Stronger" and "more selective" are different questions here.

does ipamorelin raise cortisol like hexarelin does?

Ipamorelin's original 1998 characterization paper found it stimulates GH release with minimal ACTH and cortisol co-release, in contrast to earlier secretagogues ^[1]. Hexarelin, as an older and less selective compound, is described in comparative pharmacology as having more pronounced cortisol pathway involvement. There's no dedicated modern head-to-head trial directly comparing cortisol response between the two in humans.

can you buy hexarelin or ipamorelin as an FDA-approved drug?

No. Neither appears in FDA's Drugs@FDA database of approved drug products ^[20]. Both exist only through the compounding pathway under 21 U.S.C. 353a and FDA's bulk drug substance lists ^{[21][22][23][24]}, or through unregulated sellers, which carry documented quality risks ^[26].

is there a standalone ipamorelin product available?

No. Ipamorelin is not sold as a standalone compound in the legitimate compounding channel referenced here. It's dispensed as part of a tesamorelin/ipamorelin blend, pairing ipamorelin's ghrelin-mimetic action with tesamorelin's separate GHRH-analog mechanism, not as an isolated ipamorelin-only vial.

has ipamorelin been tested in actual human clinical trials?

Yes, in a narrow context. A 2014 International Journal of Colorectal Disease study ran a prospective, randomized, controlled proof-of-concept trial testing ipamorelin against postoperative ileus in bowel resection patients ^[16]. That's a real controlled human trial, but it's specific to GI motility recovery after surgery, not to muscle gain, fat loss, or anti-aging claims.

why did ipamorelin get developed if hexarelin already existed?

Because hexarelin and earlier GHRPs like GHRP-6 stimulated GH release but also drove unwanted cortisol and prolactin responses. Researchers iterated on that pentapeptide/hexapeptide chemistry through the 1990s specifically to isolate a compound that hit the GH-release pathway with less off-target activity, which is what the 1998 papers describing ipamorelin's development and its selectivity claim ^[1][2][3] document.

do hexarelin and ipamorelin show up on drug tests?

Ipamorelin metabolites have been specifically identified in human urine after nasal administration in anti-doping-relevant research ^[13], and a 2012 metabolism study mapped how GH-releasing peptides break down in the body ^[12]. A 2026 JBJS Reviews paper on injectable peptides in sports medicine covers anti-doping implications for this peptide class broadly ^[32].

does either peptide affect bone density?

Ipamorelin does in animal models. A 1999 study found it induced longitudinal bone growth in rats ^[6], a 2000 study found it increased bone mineral content in adult female rats ^[7], and a 2001 study found it counteracted glucocorticoid-induced bone formation loss ^[8]. No comparable hexarelin-specific bone study appears in the sources reviewed here.

is hexarelin or ipamorelin better for gut motility or nausea?

Ipamorelin has the documented evidence here, not hexarelin. Rodent studies in 2009 and 2012 found ipamorelin improved gastric dysmotility in postoperative ileus models ^[14][15], which led to the 2014 human proof-of-concept trial ^[16]. A related 2024 paper found ipamorelin and anamorelin both blunted cisplatin-induced weight loss in ferrets ^[28].

what's the legal status of buying these peptides for personal use?

Legitimate access runs through compounding pharmacies operating under 21 U.S.C. 353a, using bulk substances on FDA's 503A list under 21 CFR 216.23 ^[21][22]. Buying from unregulated online sellers carries documented risk: a 2018 analysis of black market growth-promoting products found real discrepancies in labeled versus actual content ^[26].

can hexarelin or ipamorelin cause receptor desensitization with repeated use?

Repeated dosing of potent GHS-R1a agonists can theoretically blunt the pituitary's GH response over time, a known concern in this pharmacology class. Ipamorelin's lower potency and higher selectivity make it a plausible candidate for less of this effect than hexarelin, but no dedicated head-to-head desensitization trial comparing the two compounds appears in the current literature.

are hexarelin and ipamorelin used for anything besides bodybuilding?

Yes. Peer-reviewed interest spans orthopaedics ^[29], sports medicine ^[30][31][32], metabolic and endocrine conditions ^[33], gerontology ^[34], and body composition management in hypogonadal men ^[35]. Ipamorelin specifically has a GI motility research line around postoperative ileus ^[14][15][16]. None of this equals an FDA-approved indication for either compound.

Sources

1. European Journal of Endocrinology, 1998 (PMID 9849822): Ipamorelin is described as the first selective growth hormone secretagogue, stimulating GH release with minimal ACTH, cortisol, and prolactin co-release compared to earlier secretagogues
2. Journal of Medicinal Chemistry, 1998 (PMID 9733496): Documents the medicinal chemistry development of novel orally active growth hormone secretagogues, part of the lineage leading to ipamorelin
3. Journal of Medicinal Chemistry, 1998 (PMID 9733495): Describes a new series of highly potent growth hormone-releasing peptides derived from ipamorelin, showing iterative structure-activity work on the GHRP-6 scaffold
4. Neuro Endocrinology Letters, 2004 (PMID 15665799): Describes a distinct, GH-independent mechanism by which ipamorelin evokes insulin release from the pancreas in normal and diabetic rats
5. Biochemical and Biophysical Research Communications, 2001 (PMID 11162489): Found GH secretagogues can stimulate adiposity through GH-independent pathways
6. Growth Hormone & IGF Research, 1999 (PMID 10373343): Ipamorelin induced longitudinal bone growth in rats
7. The Journal of Endocrinology, 2000 (PMID 10828840): Ipamorelin and GHRP-6 increased bone mineral content in adult female rats
8. Growth Hormone & IGF Research, 2001 (PMID 11735244): Ipamorelin counteracted glucocorticoid-induced decreases in bone formation in adult rats
9. Histology and Histopathology, 2002 (PMID 12168778): Characterized the somatotroph response to chronic ipamorelin treatment in young female rats in vitro
10. Pharmaceutical Research, 1999 (PMID 10496658): Modeled the pharmacokinetics and pharmacodynamics of ipamorelin in human volunteers
11. Xenobiotica, 1998 (PMID 9879640): Evaluated the pharmacokinetics of ipamorelin and related peptidyl GH secretagogues, including nasal absorption
12. Analytical Chemistry, 2012 (PMID 23101768): Mapped the metabolism of growth hormone releasing peptides including ipamorelin
13. Drug Testing and Analysis, 2015 (PMID 25869809): Identified ipamorelin metabolites in human urine after nasal administration, relevant to anti-doping detection
14. The Journal of Pharmacology and Experimental Therapeutics, 2009 (PMID 19289567): Ipamorelin showed efficacy in a rodent model of postoperative ileus
15. Journal of Experimental Pharmacology, 2012 (PMID 27186127): Ipamorelin improved gastric dysmotility in a rodent model of postoperative ileus
16. International Journal of Colorectal Disease, 2014 (PMID 25331030): A prospective, randomized, controlled proof-of-concept study tested the ghrelin mimetic ipamorelin for management of postoperative ileus in bowel resection patients
17. Journal of Experimental Pharmacology, 2020 (PMID 32801950): Ghrelin mimetics, including ipamorelin, attenuated visceral and somatic nociception in animal models
18. Bioorganic & Medicinal Chemistry Letters, 2001 (PMID 11459660): Describes highly potent growth hormone secretagogues built as hybrids of NN703 and ipamorelin chemistry
19. Drug Testing and Analysis, 2017 (PMID 26811125): Reviews structure-activity relationships across peptidic growth hormone secretagogues including side-chain differences affecting receptor binding and off-target activity
20. FDA, Drugs@FDA database: Neither hexarelin nor ipamorelin appears as an FDA-approved drug product in this database
21. 21 U.S.C. 353a, pharmacy compounding: Establishes the statutory pathway under which compounding pharmacies may prepare certain drug substances under section 503A
22. 21 CFR 216.23, the final 503A Bulks List: Lists bulk drug substances that may be used in compounding under section 503A
23. 21 CFR 216.24, the 503B Bulks List: Establishes a separate bulk drug substance list applicable to 503B outsourcing facilities
24. FDA, bulk drug substances used in compounding under section 503A: FDA guidance page describing the criteria for bulk drug substances used in 503A compounding
25. FDA, bulk drug substances nominated for use in compounding (current list): Maintains the current list of substances nominated for evaluation for use in compounding
26. Growth Hormone & IGF Research, 2018 (PMID 29864719): Analysis of black market growth-promoting products found discrepancies between labeled and actual content
27. Growth Hormone & IGF Research, 2009 (PMID 19231263): Studied growth hormone and GH secretagogue effects on nitrogen balance and urea synthesis in steroid-treated rats
28. Physiology & Behavior, 2024 (PMID 39043357): Ipamorelin and anamorelin both inhibited cisplatin-induced weight loss in ferrets, with anamorelin showing additional anti-emetic effects via a central mechanism
29. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Reviews therapeutic peptide applications, challenges, and future directions in orthopaedics
30. The American Journal of Sports Medicine, 2026 (PMID 41476424): Provides a primer on injectable peptide therapy for orthopaedic and sports medicine physicians
31. Sports Medicine, 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance
32. JBJS Reviews, 2026 (PMID 42160466): Structured narrative review of injectable peptides in sports medicine covering evidence, safety, and anti-doping implications
33. International Journal of Molecular Sciences, 2026 (PMID 42123471): Reviews therapeutic peptides across aesthetic, metabolic, and endocrine conditions
34. Frontiers in Aging, 2026 (PMID 42021992): Reviews mechanisms and applications of therapeutic peptides in gerontology and healthy aging
35. Translational Andrology and Urology, 2020 (PMID 32257855): Examines the role of growth hormone secretagogues in managing body composition in hypogonadal males